Vaccine induced immunologic memory for hepatitis B surface antigen: Implications for policy on booster vaccination

Vaccine

Volumn 14, Issue 11, 1996, Pages 1019-1027

  West, David J ^a   Calandra, Gary B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Booster vaccination; Hepatitis B vaccine; Immunologic memory

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS B; HUMAN; IMMUNOLOGICAL MEMORY; NORMAL HUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION;

EID: 0030218036     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(96)00062-X     Document Type: Review

References (78)

1. 1 Kane, M.A. Progress on the control of hepatitis B infection through immunisation. Gut 1993, 34 Suppl. 2, S10-S12
2. 2 Sitrin, R.D., Wampler, D.E. and Ellis, R.W. Survey of licensed hepatitis B vaccines and their production processes. In: Hepatitis B Vaccines in Clinical Practice (Ed. Ellis, R.W.). Marcel Dekker, New York, 1993, pp. 83-101
3. 3 West, D.J. Scope and design of hepatitis B vaccine clinical trials. In: Hepatitis B Vaccines in Clinical Practice (Ed. Ellis, R.W.). Marcel Dekker, New York, 1993, pp 159-177
4. 4 Calandra, G.B. and West, D.J. Recommendations for prevention of hepatitis B with vaccine. In: Hepatitis B Vaccines in Clinical Practice (Ed. Ellis, R.W.). Marcel Dekker, New York, 1993, pp. 1-16
5. 5 Centers for Disease Control. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP) Morbid. Mortal. Wkly Rep. 1991, 40 RR-13, 1-25
6. 6 West, D.J., Calandra, G.B., Hesley, T.M., Ioli, V. and Miller, W.J. Control of hepatitis B through routine immunization of infants: the need for flexible schedules and new combination vaccine formulations. Vaccine 1993, 11 Suppl. 1, s21-s27
7. 7 Melnick, J.L. Historical aspects of hepatitis B vaccine. In: Hepatitis B Vaccine (Eds Maupas, P. and Guesry, P.). INSERM Symposium No. 18, Elsevier/North Holland Biomedical Press, Amsterdam, 1981, pp. 23-31
8. 8 Seeff, L.B., Wright, E.C., Zimmerman, H.J. et al. Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study. Ann. Int. Med. 1978, 88, 285-293
9. 9 Courouce-Pauty, A.-M., Naret, C., Ciancionni C., Adhemes, J.P. and Soulier, J.P. Prevention of viral hepatitis B in hemodialysis units by means of anti-HBs immunoglobulins. In: Transplantation and Clinical Immunology Volume 10 (Eds Touraine, J.L., Traeger, J., Betuel, H., Brochier, J., Dubernard, J.M., Revillard, J.P. and Triau, R.). Excerpta Medica, Amsterdam-Oxford, 1979, pp. 77-85
10. 10 Szmuness, W., Stevens, C.E., Zang, E.A., Harley, E.J. and Kellner, A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology 1981, 1, 377-385
11. 11 Francis, D.P., Hadler, S.C., Thompson, S.E. et al. The prevention of hepatitis B with vaccine. Report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann. Int. Med. 1982, 97, 362-366
12. 12 Coutinho, R. A., Lelie, N., Albrecht-Van Lent, P. et al. Efficacy of a heat inactivated hepatitis B vaccine in male homosexuals: outcome of a placebo controlled double blind trial. Br. Med. J. 1983, 286, 1305-1308
13. 13 Emini, E.A., Ellis, R.W., Miller, W.J., McAleer, W.J., Scolnick, E.M. and Gerety, R.J. Production and immunological analysis of recombinant hepatitis B vaccine. J. Infect. 1986, 13 Suppl. A, 3-9
14. 14 West, D.J. Clinical experience with hepatitis B vaccines. Am. J. Infect. Control 1989, 17, 172-180
15. 15 Maynard, J.E., Kane, M.A., Alter, M.J. and Hadler, S.C. Control of hepatitis B by immunization: global perspectives. In: Viral Hepatitis and Liver Disease (Ed. Zuckerman, A.J.). Alan R. Liss, New York, 1988, pp. 967-969
16. 16 Stevens, C.E., Taylor, P.E., Tong, M.J., Toy, P.T., Vyas, G.N., Zang, E. and Krugman, S. Prevention of perinatal hepatitis B virus infection with hepatitis B immune globulin and hepatitis B vaccine. In: Viral Hepatitis and Liver Disease (Ed. Zuckerman, A.J.). Alan R. Liss, New York, 1988, pp. 982-988
17. 17 Centers for Disease Control. Recommendation of the Immunization Practices Advisory Committee (ACIP). Recommendations for protection against viral hepatitis. Morbid. Mortal. Wkly. Rep. 1985, 34, 313-324, 329-335
18. 18 Centers for Disease Control. Recommendations of the Immunization Practices Advisory Committee. Update on hepatitis B prevention. Morbid. Mortal. Wkly. Rep. 1987, 36, 353-360, 366
19. 19 International Group. Immunisation against hepatitis B. Lancet 1988, 1, 875-876
20. 20 World Health Organization. Informal consultation on quadrivalent diphtheria-tetanus-pertussis-hepatitis B vaccine. Final report. World Health Organization, Geneva, 1992
21. 21 Brotman, B. and Prince, A.M. Occurrence of AUSAB test positivity unrelated to prior exposure to hepatitis B virus. J. Infect. Dis. 1984, 150, 714-720
22. 22 Linneman, C.C. and Askey, P.A. Susceptibility to hepatitis B despite high titre anti-HBs antibody. Lancet 1984, 1, 346-347
23. 23 Sherertz, R.J., Spindel, E. and Hoofnagle, J.H. Antibody to hepatitis B surface antigen may not always indicate immunity to hepatitis B virus infection. New Engl. J. Med. 1983, 309, 1519
24. 24 Trepo, G.G. and Prince, A.M. Absence of complete homologous immunity in hepatitis B infection after massive exposure. Ann. Int. Med. 1976, 85, 427-430
25. 25 Hoofnagle, J.H., Gerety, R.J., Smallwood, L.A. and Barker, L.F. Subtyping of hepatitis B surface antigen and antibody by radioimmunoassay. Gastroenterology 1977, 72, 290-296
26. 26 Koziol, D.E., Alter, H.J., Kirchner, J.P. and Holland, P.V. The development of HBsAg-positive hepatitis despite the previous existence of antibody to HBsAg. J. Immun. 1976, 117, 2260-2262
27. 27 Waters, J.A., Kennedy, M., Voet, P. et al. Loss of the common "a" determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J. Clin. Invest. 1992, 90, 2543-2547
28. 28 Feitelson, M.A, Biology of disease. Biology of hepatitis B virus variants. Lab. Invest. 1994, 71, 324-349
29. 29 Chabaud, M., Depril, N., LeCann, P. et al. Detection of hepatitis B virus DNA by polymerase chain reaction in vaccinated and non-vaccinated Senegalese children. Arch. Virol. 1993, 8 Suppl., 123-131
30. 30 Jilg, W., Schmidt, M. and Deinhardt, F. Four-year experience with a recombinant hepatitis B vaccine. Infection 1989, 17, 70-76
31. 31 Geseman, M. and Scheiermann, N. Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence. Vaccine 1995, 13, 443-447
32. 32 Andre, F.E. and Safary, A. Clinical experience with a yeast-derived hepatitis B vaccine. In: Viral Hepatitis and Liver Disease (Ed. Zuckerman, A.J.). Alan R. Liss, New York, 1988, pp. 1025-1030
33. 33 Roitt I., Brostoff, J. and Dale, D. Immunology, 2nd edn. Gower Medical Publishing, London, 1989
34. 34 Wismans, P.J., van Hattum, J., Mudde, G.G., Endeman, H.J., Poel, J. and deGast, G.C. Is booster injection with hepatitis B vaccine necessary in healthy responders? A study of the immune response. J. Hepat. 1989, 8, 236-240
35. 35 Trivello, R., Chiaramonte, M., Ngatchu, T. et al. Persistence of anti-HBs antibodies in health care personnel vaccinated with plasma-derived hepatitis B vaccine and response to recombinant DNA HB booster vaccine. Vaccine 1995, 13, 139-141
36. 36 Bucher, B., Francioli, P., Geudelin, B., Fritzell, B., Lavanchy, D. and Frei, P.C. Immunogenicity of a recombinant pre-S2-containing hepatitis B vaccine versus plasma-derived vaccine administered as a booster. Eur. J. Clin. Microbiol. Infect. Dis. 1994, 13, 212-217
37. 37 Krugman, S. and Davidson, M. Hepatitis B vaccine: prospects for duration of immunity. Yale J. Biol. Med. 1987, 60, 333-338
38. 38 Milne, A. and Waldon, J.A. Recombinant DNA hepatitis B vaccination in teenagers: effect of a booster at 5-1/2 years J. Infect. Dis. 1992, 166, 942
39. 39 Milne, A., Krugman, S., Waldon, J.A. et al. Hepatitis B vaccination in children: five year booster study. N.Z. Med. J. 1992, 105, 336-338
40. 40 Milne, A., Hopkirk, N. and Moyes, C.D. Hepatitis B vaccination in children: persistence of immunity at 9 years. J. Med. Virol. 1994, 44, 113-114
41. 41 West, D.J., Watson, B., Lichtman, J., Hesley, T.M. and Hedberg, K. Persistence of immunologic memory for twelve years in children given hepatitis B vaccine in infancy. Pediatr. Infect. Dis. J. 1994, 13, 745-747
42. 42 Resti, M., DiFrancesco, G., Azzari, C., Rossi, M.E. and Vierucci, A. Anti-HBs and immunological memory to HBV vaccine: implication for booster timing. Vaccine 1993, 11, 1079
43. 43 Gonzalez, M.L., Gonzalez, J.B., Salva, F. and Lardinois, R. A 7-year follow-up of newborns vaccinated against hepatitis B. Vaccine 1993, 11, 1033-1036
44. 44 Lee, S.-D., Lo, K.-J., Tsai, Y.-T., Chan, C.-Y. and Wu, T-C. The second booster for the previously hepatitis B vaccine-immunized high-risk children. In: Viral Hepatitis and Liver Disease (Eds Hollinger, F.B., Lemon, S.M. and Margolis, H.S.). Williams and Wilkins, Baltimore, 1991, pp. 776-778
45. 45 Wismans, P.J., van Hattum, J., De Gast, G.C. et al. The spot-ELISA: a sensitive in vitro method to study the immune response to hepatitis B surface antigen. Clin. exp. Immun. 1989, 78, 75-78
46. 46 van Hattum, J., Maikoe, T., Poel, J. and DeGast, G.C. In vitro anti-HBs production by individual B cells of responders to hepatitis B vaccine who subsequently lost antibody. In: Viral Hepatitis and Liver Disease (Eds Hollinger, F.B., Lemon, S.M. and Margolis, H.S.). Williams and Wilkins, Baltimore, 1991, pp. 774-776
47. 47 van Hattum, J., Maikoe, T., Poel, J. and DeGast, G.C. Persistence of immune memory in responders to hepatitis B vaccination who subsequently lost serum anti-HBs. Neth. J. Med. 1991, 39, A74
48. 48 Hadler, S.C., Coleman, P.J., O'Malley, P., Judson, F.N. and Altman, N. Evaluation of long-term protection by hepatitis B vaccine for seven to nine years in homosexual men. In: Viral Hepatitis and Liver Disease (Eds Hollinger, F.B., Lemon, S.M., and Margolis, H.S.). Williams and Wilkins, Baltimore, 1991, pp. 766-768
49. 49 Stevens, C.E., Taylor, P.E., Tong, M.J., Toy, P.T. and Vyas, G.N. Hepatitis B vaccine: an overview. In: Viral Hepatitis and Liver Disease (Eds Vyas G.N., Dienstag, J.L. and Hoofnagle, J.H.). Grune and Stratton, Orlando, 1984, pp. 275-291
50. 50 Stevens, C.E., Toy, P.T., Taylor, P.E., Lee, T. and Yip, H-Y. Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long-term protection. Pediatrics 1992, 90, 170-173
51. 51 Wainwright, R.B., McMahon, B.J., Bulkow, L.R. et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. J. Am. Med. Assoc. 1989, 261, 2362-2366
52. 52 Wainwright, R.B., McMahon, B.J., Bulkow, L.R., Parkinson, A.J. and Harpster, A.P. Protection provided by hepatitis B vaccine in a Yupik Eskimo population. Arch. Intern. Med. 1991, 151, 1634-1636
53. 53 Zhang, M., Lie, K., Ding, L. and Smego, R.A. Jr. Duration and efficacy of immune response to hepatitis B vaccine in high-risk Chinese adolescents. Clin. Infect. Dis. 1993, 16, 165-167
54. 54 Lai, C.-L., Wong, B.C.-Y., Yeoh, E.-K., Lim, W.-L., Chang, W.-K. and Lin, H.-J. Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: immunogenicity and anamnestic responses. Hepatology 1993, 18, 763-767
55. 55 Whittle, H.C., Maine, N., Pilkington, J. et al. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet 1995, 345, 1089-1092
56. 56 Coursaget, P., Chotard, J. and Vincelot, P. Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal). Lancet 1986, 2, 1143-1145
57. 57 Coursaget, P., Leboulleux, D., Soumare, M. et al. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. J. Hepat. 1994, 21, 250-254
58. 58 Delage, G., Remy-Prince, S., Ducic, S., Pierri, E., Montplaisir, S. and The Montreal Hepatitis B Virus Immunization Study Group. Combined passive-active immunization against the hepatitis B virus of 132 newborns of chronic carrier mothers: long term results. Pediatr. Infect. Dis. J. 1988, 7, 769-776
59. 59 Delage, G., Remy-Prince, S. and Montplaisir, S. Combined active-passive immunization against the hepatitis B virus: five year follow-up of children born to hepatitis B surface antigen positive mothers. Pediatr. Infect. Dis. J. 1993, 12, 126-130
60. 60 Ding, L., Zhang, M., Wang, Y., Zhou, S., Kong, W. and Smego, R.A. Jr. A 9-year follow-up study of the immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates. Clin. Infect Dis. 1993, 17, 475-479
61. 61 Hwang, L.-Y., Lee, C.-Y. and Beasley, R.P. Five-year follow-up of HBV vaccination with plasma-derived vaccine in neonates: evaluation of immunogenicity and efficacy against perinatal transmission. In: Viral Hepatitis and Liver Disease (Eds Hollinger F.B., Lemon, S.M. and Margolis, H.S.). Williams and Wilkins, Baltimore, 1991, pp. 759-761
62. 62 Lee, P.-I., Lee, C.-Y., Huang, L.-M. and Chang, M.-H. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. J. Pediatr. 1995, 126, 716-721
63. 63 Lo, K.-J., Lee, S.-D., Tsai, Y.-T. et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in infants born to HBeAg-positive HBsAg-carrier mothers. Hepatology 1988, 8, 1647-1650
64. 64 Beasley, R.P. and Hwang, L.-Y. Postnatal infectivity of hepatitis B surface antigen carrier mothers. J. Infect. Dis. 1983, 147, 185-190
65. 65 Goilav, C. and Piot, P. Vaccination against hepatitis B in homosexual men. Am. J. Med. 1989, 87suppl. 3A, 21s-25s
66. 66 Seaworth, B., Drucker, J., Starling, J., Drucker, R., Stevens, C. and Hamilton, J. Hepatitis B vaccines in patients with chronic renal failure before dialysis. J. Infect. Dis. 1988, 157, 332-337
67. 67 Mendenhall, C., Roselle, G.A., Lybecker, L.A. et al. Hepatitis B vaccination. Response of alcoholics with and without liver injury. Dig. Dis. Sci. 1988, 33, 263-269
68. 68 Pozzilli, P., Arduni, P., Visalli, N. et al. Reduced protection against hepatitis B virus following vaccination in patients with type 1 (insulin-dependent) diabetes. Diabetologia 1987, 30, 817-819
69. 69 Carey, W., Pimentel, R., Westveer, M.K., Vogt, D. and Broughan, T. Failure of hepatitis B immunization in liver transplant recipients: results of a prospective trial. Am. J. Gastroenterol. 1990, 85, 1590-1592
70. 70 Berberoglu, S., Buyukpamukcu, M., Sarialioglu, F., Akyuz, C. and Ithan, I. Hepatitis B vaccination in children with cancer Pediatr. Hematol. Oncol. 1995, 12, 171-178
71. 71 Averhoff, F., Mahoney, F., Coleman, P., Schatz, G. and Hurwitz, E. Response to hepatitis B vaccination: a randomized trial comparing the immunogenicity of Engerix-B and Recombivax-HB. 34th Intersci. Conf. Antimicrob. Agents Chemotherapy, Orlando, FL, 1994
72. 72 Shaw, F.E., Guess, H.A., Roets, J.M. et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 1989, 7, 425-430
73. 73 Wood, R.C., MacDonald, K.L., White, K.E., Hedberg, C.H., Hanson, M. and Osterholm, M.J. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. J. Am. Med. Assoc. 1993, 270, 2935-2939
74. 74 Roome, A.J., Walsh, S.J., Carter, M.L. and Hadler, J.L. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. J. Am. Med. Assoc. 1993, 270, 2931-2934
75. 75 Winter, A.P., Follett, E.A.C., McIntyre, J., Stewart, J. and Symington, I.S. Influence of smoking on immunological responses to hepatitis B vaccine. Vaccine 1994, 12, 771-772
76. 76 de Rave, S., Heijtink, R.A., Bakker-Bendik, M., Boot, J. and Schalm, S.W. Immunogenicity of standard and low dose vaccination using yeast-derived recombinant hepatitis B surface antigen in elderly volunteers. Vaccine 1994, 12, 532-534
77. 77 Centers for Disease Control. Protection against viral hepatitis. Recommendations of the Immunization Practices Advisory Committee [ACIP]. Morbid. Mortal. Wkly. Rep. 1990, 39 No. RR-2, 1-26
78. 78 Task Force on Adults Immunization. Guide for Adult Immunization, 2nd edn. American College of Physicians, Philadelphia, 1990